摘要
Post-translational modifications(PTMs)involve the addition or removal of specific chemical groups to proteins in a covalent manner,which regulates their activity,localization,folding,and interactions with other biological macromolecules.PTMs contribute to the diversity of proteins,enabling them to carry out complex life processes1.It has been well-recognized that abnormal PTMs are closely related to the occurrence,development,and therapeutic resistance of malignant tumors1.Taking multiple myeloma(MM),the second most common hematologic malignancy,as an example,the delicate balance of protein homeostasis and post-translational regulation is crucial to its disease progression2.These insights have led to the success of bortezomib,the first-line treatment for MM patients3.To date,more than 650 types of PTMs have been described.For most of these modifications,there lacks an effective approach to targeting PTMs for therapeutic prospects,which constitutes a cutting-edge scientific area in the field of drug development.
